Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing an expected acquired in-process research and development (IPR&D) charge of approximately $83 million on a pre-tax basis for the third quarter of 2025. This charge is primarily linked to an $80 million upfront payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The company anticipates this IPR&D charge will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.68 for the quarter.
Key Highlights
- 1Expected $83 million pre-tax IPR&D charge for Q3 2025.
- 2Charge primarily driven by an $80 million upfront payment related to a license agreement with Hansoh Pharmaceuticals Group Company Limited.
- 3Anticipated negative impact of approximately $0.68 per diluted share on both GAAP and non-GAAP net income for Q3 2025.
- 4IPR&D charges are not typically forecasted due to their inherent uncertainty.
- 5Financial results for Q3 2025 are preliminary and subject to closing procedures.
- 6The information provided is not considered "filed" for purposes of Section 18 of the Securities Exchange Act.
- 7Includes standard forward-looking statements and a note on non-GAAP financial measures.